Like Biotech Stocks? View our Biotech Stocks Directory Get News Alerts on Biotech Stocks
#Medtech Stocks in the News: Electromedical Technologies (OTCQB: $EMED) Produces $4.2 Million in Device Inventory to Meet Demand |
Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering |
Biotech Stock News: NervGen Pharma (TSXV: NGEN) (OTCQX: NGENF) Reports Third Quarter 2020 Results and Provides Operational Update |
Medical Technology Stock News: Electromedical Technologies (OTCQB: $EMED) Produces $4.2 Million in Device Inventory to Meet Demand |
Lexicon Shares Rise 40% upon Achieving Primary Endpoints in Two Phase 3 Heart Failure Studies |
Coronavirus / Biotech Stock News Bites: Moderna's (NASDAQ: $MRNA) COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study |
Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial |
Biopharma Posts 'Impressive' Q3/20 Sales Amid Pandemic |
Draganfly Screening Technology Battles Campus, Public Facilities Health Challenges |
Pfizer and BioNTech Announce Extremely Positive Phase 3 COVID-19 Vaccine Trial Data; Production of 1.3 Billion Doses in 2021 Planned |
First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.
iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.
iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.
iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.
iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.
Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
The Impact of Gynecomastia on Your Mental Health and How to Deal With the Condition - September 8, 2020
Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020
Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020
The Rise Of The At-Home Testing Market - January 16, 2020
Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019
5 Key Tips For Renting a Boardroom - August 14, 2018
How to Go About Choosing a Medical Malpractice Lawyer - February 13, 2018
RETRANSMISSION: Bee Vectoring Technologies Enters New Phase to Accelerate Revenue Growth in 2021 |
MustGrow Announces Investor Initiatives, Presentation Today at the Future of Food Investment Conference |
Bee Vectoring Technologies Enters New Phase to Accelerate Revenue Growth in 2021 |
American Aires Launches 'Lifetune' - a 5G Optimized, Ground-Breaking New Line of EMR Modulation Technology Products for Home, Office & Pets |
PreveCeutical Files Provisional Patent Application for its COVID-19 Formulation |
Subscribe to Biotech News RSS